Advertisement

Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination

  • David M Mannino
    Correspondence
    Requests for reprints should be addressed to David M. Mannino, MD, National Center for Environmental Health, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-17, Atlanta, Georgia 30333, USA
    Affiliations
    Air Pollution and Respiratory Health Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Search for articles by this author
  • Earl S Ford
    Affiliations
    Air Pollution and Respiratory Health Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Search for articles by this author
  • Stephen C Redd
    Affiliations
    Air Pollution and Respiratory Health Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Search for articles by this author
      Although chronic obstructive pulmonary disease (COPD) and restrictive lung diseases are important causes of morbidity and mortality in the United States (
      • Mannino D.M.
      • Homa D.M.
      • Akinbami L.
      • et al.
      Surveillance for chronic obstructive pulmonary disease—United States, 1971–2000.
      ,
      • King Jr, T.E.
      Respiratory bronchiolitis-associated interstitial lung disease.
      ,
      • Gay S.E.
      • Kazerooni E.A.
      • Toews G.B.
      • et al.
      Idiopathic pulmonary fibrosis predicting response to therapy and survival.
      ), a large proportion of the morbidity and mortality is not pulmonary (
      • Camilli A.E.
      • Robbins D.R.
      • Lebowitz M.D.
      Death certificate reporting of confirmed airways obstructive disease.
      ). This raises the possibility that lung disease may be an indicator of susceptibility to the development of other diseases or may be associated with systemic inflammation that leads to other diseases (
      • Danesh J.
      • Pepys M.B.
      C-reactive protein in healthy and in sick populations.
      ,
      • Nijmeijer R.
      • Lagrand W.K.
      • Visser C.A.
      • et al.
      CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction?.
      ). Previous analyses of the relation between lung function and markers of inflammation (
      • Cirillo D.J.
      • Agrawal Y.
      • Cassano P.A.
      Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey.
      ,
      • Mendall M.A.
      • Patel P.
      • Ballam L.
      • et al.
      C reactive protein and its relation to cardiovascular risk factors a population based cross sectional study.
      ) have not looked at restrictive lung disease separately.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mannino D.M.
        • Homa D.M.
        • Akinbami L.
        • et al.
        Surveillance for chronic obstructive pulmonary disease—United States, 1971–2000.
        MMWR CDC Surveill Summ. 2002; 50: 1-16
        • King Jr, T.E.
        Respiratory bronchiolitis-associated interstitial lung disease.
        Clin Chest Med. 1993; 14: 693-698
        • Gay S.E.
        • Kazerooni E.A.
        • Toews G.B.
        • et al.
        Idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 1998; 157: 1063-1072
        • Camilli A.E.
        • Robbins D.R.
        • Lebowitz M.D.
        Death certificate reporting of confirmed airways obstructive disease.
        Am J Epidemiol. 1991; 133: 795-800
        • Danesh J.
        • Pepys M.B.
        C-reactive protein in healthy and in sick populations.
        Eur Heart J. 2000; 21: 1564-1565
        • Nijmeijer R.
        • Lagrand W.K.
        • Visser C.A.
        • et al.
        CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction?.
        Int Immunopharmacol. 2001; 1: 403-414
        • Cirillo D.J.
        • Agrawal Y.
        • Cassano P.A.
        Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey.
        Am J Epidemiol. 2002; 155: 842-848
        • Mendall M.A.
        • Patel P.
        • Ballam L.
        • et al.
        C reactive protein and its relation to cardiovascular risk factors.
        BMJ. 1996; 312: 1061-1065
        • National Center for Health Statistics
        Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–1994.
        Vital Health Stat. 1994; 1: 1-407
        • Standardization of spirometry—1987 update
        Statement of the American Thoracic Society.
        Am Rev Respir Dis. 1987; 136: 1285-1298
        • Hankinson J.L.
        • Odencrantz J.R.
        • Fedan K.B.
        Spirometric reference values from a sample of the general U.S. population.
        Am J Respir Crit Care Med. 1999; 159: 179-187
        • Pauwels R.A.
        • Buist A.S.
        • Calverley P.M.
        • et al.
        Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global initiative for chronic Obstructive Lung Disease (GOLD) workshop summary.
        Am J Respir Crit Care Med. 2001; 163: 1256-1276
        • Gunter E.W.
        • Lewis B.
        • Koncikowski S.
        Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Atlanta, Georgia1996
        • Visser M.
        • Bouter L.M.
        • McQuillan G.M.
        • et al.
        Elevated C-reactive protein levels in overweight and obese adults.
        JAMA. 1999; 282: 2131-2135
        • SAS Institute I
        SAS Language. SAS Institute, Cary, North Carolina1990
        • Shah B.V.
        • Barnwell B.G.
        • Bieler G.S.
        SUDAAN User’s Manual, Release 7.5. Research Triangle Institute, Research Triangle Park, North Carolina1997
        • Burrows B.
        • Bloom J.W.
        • Traver G.A.
        • Cline M.G.
        The course and prognosis of different forms of chronic airways obstruction in a sample from the general population.
        N Engl J Med. 1987; 317: 1309-1314
        • Marcus E.B.
        • Buist A.S.
        • Maclean C.J.
        • Yano K.
        Twenty-year trends in mortality from chronic obstructive pulmonary disease.
        Am Rev Respir Dis. 1989; 140: S64-S68
        • Zielinski J.
        • MacNee W.
        • Wedzicha J.
        • et al.
        Causes of death in patients with COPD and chronic respiratory failure.
        Monaldi Arch Chest Dis. 1997; 52: 43-47
        • Wouters E.F.
        • Creutzberg E.C.
        • Schols A.M.
        Systemic effects in COPD.
        Chest. 2002; 121: 127S-130S
        • Agusti A.G.
        Systemic effects of chronic obstructive pulmonary disease.
        Novartis Found Symp. 2001; 234: 242-249
        • Jeffery P.K.
        Remodeling in asthma and chronic obstructive lung disease.
        Am J Respir Crit Care Med. 2001; 164: S28-S38
        • Ridker P.M.
        • Stampfer M.J.
        • Rifai N.
        Novel risk factors for systemic atherosclerosis.
        JAMA. 2001; 285: 2481-2485
        • Lagrand W.K.
        • Visser C.A.
        • Hermens W.T.
        • et al.
        C-reactive protein as a cardiovascular risk factor.
        Circulation. 1999; 100: 96-102
        • Tracy R.P.
        • Psaty B.M.
        • Macy E.
        • et al.
        Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects.
        Arterioscler Thromb Vasc Biol. 1997; 17: 2167-2176
        • Schachter L.M.
        • Salome C.M.
        • Peat J.K.
        • Woolcock A.J.
        Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness.
        Thorax. 2001; 56: 4-8
        • Prior C.
        • Knight R.A.
        • Herold M.
        • et al.
        Pulmonary sarcoidosis.
        Eur Respir J. 1996; 9: 47-53
        • De Maat M.P.
        • Kluft C.
        Determinants of C-reactive protein concentration in blood.
        Ital Heart J. 2001; 2: 189-195
        • Dong Q.
        • Wright J.R.
        Expression of C-reactive protein by alveolar macrophages.
        J Immunol. 1996; 156: 4815-4820
        • Ikuta T.
        • Okubo H.
        • Ishibashi H.
        • et al.
        Human lymphocytes synthesize C-reactive protein.
        Inflammation. 1986; 10: 223-232
        • Falsey A.R.
        • Walsh E.E.
        • Francis C.W.
        • et al.
        Response of C-reactive protein and serum amyloid A to influenza A infection in older adults.
        J Infect Dis. 2001; 183: 995-999
        • Wu T.
        • Dorn J.P.
        • Donahue R.P.
        • et al.
        Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin.
        Am J Epidemiol. 2002; 155: 65-71
        • Danesh J.
        • Appleby P.
        Coronary heart disease and iron status.
        Circulation. 1999; 99: 852-854
        • Hunter K.A.
        • Garlick P.J.
        • Broom I.
        • et al.
        Effects of smoking and abstention from smoking on fibrinogen synthesis in humans.
        Clin Sci (Colch). 2001; 100: 459-465
        • Fu A.
        • Sreekumaran N.K.
        Age effect on fibrinogen and albumin synthesis in humans.
        Am J Physiol. 1998; 275: E1023-E1030
        • Lowe G.
        • Rumley A.
        • Woodward M.
        • Vessey M.
        C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy.
        Thromb Haemost. 2000; 84: 730-731